PA
MRNS

Parallel Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Parallel Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-60
Closed -$483 – 3505
2023
Q3 		$483 Hold
60
– – ﹤0.01% 3112
2023
Q2 		$652 Hold
60
– – ﹤0.01% 3043
2023
Q1 		$414 Buy
+60
New +$376 ﹤0.01% 3160
2020
Q4 		– Sell
-26,245
Closed -$337K – 2763
2020
Q3 		$337K Hold
26,245
– – 0.02% 396
2020
Q2 		$266K Buy
+26,245
New +$241K 0.02% 453

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Parallel Advisors's MRNS Position: Q4 2023 in Review

Parallel Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2023, closing a stake of 60 shares — an estimated $483 sold.

Parallel Advisors first reported a position in MRNS in Q2 2020 and held it in 5 quarters. The position peaked at $337K in Q3 2020. 105 funds tracked by Wall St. Rank hold MRNS as of Q4 2023.

  • Parallel Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • Parallel Advisors sold 60 Marinus Pharmaceuticals, Inc shares in Q4 2023, an estimated $483.
  • Parallel Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q2 2020 and held it in 5 quarters.
  • Parallel Advisors's Marinus Pharmaceuticals, Inc position peaked at $337K in Q3 2020.
  • 105 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2023.

Based on Parallel Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.